non-small cell lung cancer (NSCLC)
Conditions
Interventions
Experimental group:Antirotinib hydrochloride capsules and radioactive 125I seeds were implanted for simultaneous therapy
Sponsors
Zhoukou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Signed informed consent, good compliance; 2. Aged 18-75 years (calculated on the date of signing the informed consent); 3. Patients with advanced non-small cell lung cancer confirmed by pathology or imaging, including untreated or unresectable, slow growth, and high differentiation; 4. KPS functional status score (KPS) >=60 points; 5. Expected survival >=3 months; 6. Neutrophil absolute value >=1.5x10^9/L, platelet >=70x10^9/L, hemoglobin >=90g/L; Coagulation function: prothrombin time < 15s, activated partial thrombin time < 50s; 7. Renal function: normal creatinine and urea nitrogen; Liver function: transaminase does not exceed 3 times the normal high limit; Electrocardiogram is normal; 8. No active infection; 9. According to the researchers' judgment, the treatment plan containing androtinib combined with 125I seed implantation is to be carried out.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating patients; 2. Allergic to anrotinib or its excipients; 3. Central lung squamous cell carcinoma; 4. With the risk of large hemoptysis; 5. Aversion to fluid quality, unable to tolerate or cooperate with percutaneous puncture; 6. Mass diameter > 8cm; Multiple systemic metastases; Multiple nodules in lung, single lung > 3, double lung > 5; 7. Have active, known, or suspected autoimmune diseases (including but not limited to: Uveitis, enteritis, hepatitis, pituitaritis, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchodilator treatment, etc.). Patients with hypothyroidism who only need hormone replacement therapy, skin conditions that do not require systemic treatment (such as vitiligo, psoriasis or alopecia) are eligible; 8. Myocardial infarction, severe/unstable angina pectoris, NYHA grade 2 or above cardiac insufficiency, and poorly controlled arrhythmias occurred within 6 months prior to study entry (including QTcF interval male >450 ms, female > 470 ms, QTcF interval calculated by Fridericia formula), symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism); 9. Patients receiving hematopoietic stem cells or organ transplants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Film degree exam; | — |
Countries
China
Contacts
Public ContactLiu Yong
Zhoukou Central Hospital
Outcome results
None listed